Home / CABA : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does CABA make money? Does CABA have pricing power? What's the Earnings Whisper? Will CABA profit more as the business scales? What is CABA's management track record? Is CABA's current price justified?

Cabaletta Bio, Inc.

$2.91 +$0.70 (+31.67%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$2.73

Day Range

$2.71$3.04

Year Range

$1.82$4.23

Market Cap

474.49M

AVG Volume

4.71M

Trailing/Forward PE

-1.84/-

PEG ratio

0.15

Dividend Yield

Next Earnings Date

2026-11-09

Primary Exchange

NASDAQ

Net Income (USD)

CABA Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-51.02M
26 Q1	-43.52M
25 Q4	-41.92M
25 Q3	-44.87M
25 Q2	-45.13M
25 Q1	-35.94M
24 Q4	-32.59M
24 Q3	-30.63M
24 Q2	-27.6M
24 Q1	-25.05M

Operating Income (USD)

CABA Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-52.02M
26 Q1	-44.3M
25 Q4	-42.61M
25 Q3	-46.59M
25 Q2	-45.91M
25 Q1	-37.14M
24 Q4	-33.78M
24 Q3	-33.05M
24 Q2	-30.28M
24 Q1	-28.03M

EBITDA (USD)

CABA EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-49.42M
26 Q1	-42.54M
25 Q4	-41.02M
25 Q3	-43.94M
25 Q2	-44.09M
25 Q1	-35.16M
24 Q4	-23.29M
24 Q3	-30.2M
24 Q2	-27.18M
24 Q1	-24.65M

Cash Flows (USD)

CABA Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	-41.51M
26 Q1	-42.56M
25 Q4	-35.55M
25 Q3	-34.59M
25 Q2	-30.59M
25 Q1	-31.59M
24 Q4	-23.5M
24 Q3	-20.58M
24 Q2	-21.56M
24 Q1	-24.8M

EPS (USD)

CABA EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.34
26 Q1	-0.39
25 Q4	-0.41
25 Q3	-0.44
25 Q2	-0.73
25 Q1	-0.73
24 Q4	-0.65
24 Q3	-0.62
24 Q2	-0.56
24 Q1	-0.51

Expenses (USD)

CABA Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	52.02M
26 Q1	44.3M
25 Q4	42.82M
25 Q3	46.67M
25 Q2	46.07M
25 Q1	37.92M
24 Q4	34.16M
24 Q3	33.3M
24 Q2	31.05M
24 Q1	28.84M

Cash & Debt (USD)

CABA Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	225.1M
26 Q1	116.64M
25 Q4	133.6M
25 Q3	159.93M
25 Q2	194.68M
25 Q1	131.83M
24 Q4	163.96M
24 Q3	183.01M
24 Q2	203.22M
24 Q1	223.84M

Debt ratios

CABA Debt ratios by quarter
Period	Debt ratios
26 Q2	1.13
26 Q1	0.53
25 Q4	0.65
25 Q3	0.92
25 Q2	1.28
25 Q1	0.89
24 Q4	1.41
24 Q3	1.64
24 Q2	2.21
24 Q1	2.86

Return on Capital

CABA Return on Capital by quarter
Period	Return on Capital
26 Q2	-24.23%
26 Q1	-42.12%
25 Q4	-37.41%
25 Q3	-32.17%
25 Q2	-25.28%
25 Q1	-29.57%
24 Q4	-21.39%
24 Q3	-17.58%
24 Q2	-13.83%
24 Q1	-11.3%

Shares Outstanding

CABA Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	151.16M
26 Q1	112.03M
25 Q4	102.26M
25 Q3	102.26M
25 Q2	61.88M
25 Q1	49.47M
24 Q4	50.13M
24 Q3	48.94M
24 Q2	48.94M
24 Q1	49.3M

Book Value Per Share (USD)

CABA Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	1.39
26 Q1	0.92
25 Q4	1.1
25 Q3	1.36
25 Q2	2.88
25 Q1	2.46
24 Q4	3.04
24 Q3	3.56
24 Q2	4.08
24 Q1	4.5

Total Assets (USD)

CABA Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	256.73M
26 Q1	148.15M
25 Q4	165.08M
25 Q3	189.76M
25 Q2	224.5M
25 Q1	165.14M
24 Q4	185.05M
24 Q3	204.41M
24 Q2	217.42M
24 Q1	240.46M

Employee Count

CABA Employee Count by quarter
Period	Employee Count
2025	154
2024	161
2023	101
2022	58
2021	53
2020	33
2019	22

Free Cash Flow Yield

CABA Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-35.06%
Sep 26	-37.37%
Sep 26	-29.4%
Aug 26	-32.7%
Aug 26	-32.59%
Aug 26	-37.1%
Aug 26	-45.84%
Jul 26	-47.72%
Jul 26	-47.55%
Jul 26	-45.2%
Jul 26	-42.92%
Jul 26	-40.09%
Jun 26	-42.07%
Jun 26	-45.04%
Jun 26	-42.49%
Jun 26	-39.35%
May 26	-33.84%
May 26	-35.04%
May 26	-38.64%
May 26	-33.35%
May 26	-44.01%
Apr 26	-43.86%
Apr 26	-37.61%
Apr 26	-41.34%
Apr 26	-43.71%
Mar 26	-48.28%
Mar 26	-40%
Mar 26	-38.43%
Mar 26	-37.1%
Feb 26	-35.42%
Feb 26	-40.41%
Feb 26	-42%
Feb 26	-46.85%
Jan 26	-45.76%
Jan 26	-36.98%
Jan 26	-53.45%
Jan 26	-56%
Jan 26	-53.21%
Dec 25	-53.7%
Dec 25	-49.2%
Dec 25	-49.83%
Dec 25	-46.12%
Nov 25	-45.76%
Nov 25	-56.54%
Nov 25	-50.91%
Nov 25	-67.34%
Oct 25	-47.56%
Oct 25	-69.52%
Oct 25	-60.25%
Oct 25	-74.01%
Oct 25	-70.37%
Sep 25	-72.76%
Sep 25	-78.41%
Sep 25	-93.32%
Sep 25	-101.01%
Aug 25	-118.42%
Aug 25	-105.99%
Aug 25	-100.41%
Aug 25	-126.26%
Aug 25	-136.47%
Jul 25	-118.39%
Jul 25	-117.68%
Jul 25	-112.94%
Jul 25	-120.56%
Jun 25	-125.17%
Jun 25	-109.79%
Jun 25	-98.75%
Jun 25	-79.24%
May 25	-105.09%
May 25	-112.3%
May 25	-96.81%
May 25	-151.59%
May 25	-134.62%
Apr 25	-142.04%
Apr 25	-163.99%
Apr 25	-146.66%
Apr 25	-162.51%
Mar 25	-110.17%
Mar 25	-98.14%
Mar 25	-93.83%
Mar 25	-92.3%
Feb 25	-94.34%
Feb 25	-82.89%
Feb 25	-63.01%
Feb 25	-64.44%
Jan 25	-71.45%
Jan 25	-68.31%
Jan 25	-62.32%
Jan 25	-82.1%
Jan 25	-71.15%
Dec 24	-74.57%
Dec 24	-71.75%
Dec 24	-60.55%
Dec 24	-51.75%
Nov 24	-44.7%
Nov 24	-91.32%
Nov 24	-56.36%
Nov 24	-34.43%
Nov 24	-41.67%
Oct 24	-39.54%

Price to Book

CABA Price to Book by quarter
Period	Price to Book
Sep 26	2.09
Sep 26	1.96
Sep 26	2.49
Aug 26	2.24
Aug 26	2.25
Aug 26	1.97
Aug 26	3.03
Jul 26	2.91
Jul 26	2.92
Jul 26	3.07
Jul 26	3.23
Jul 26	3.46
Jun 26	3.3
Jun 26	3.08
Jun 26	3.26
Jun 26	3.52
May 26	4.1
May 26	3.96
May 26	3.59
May 26	3.54
May 26	2.68
Apr 26	2.69
Apr 26	3.14
Apr 26	2.86
Apr 26	2.7
Mar 26	2.45
Mar 26	2.16
Mar 26	2.24
Mar 26	2.32
Feb 26	2.43
Feb 26	2.13
Feb 26	2.05
Feb 26	1.84
Jan 26	1.88
Jan 26	2.33
Jan 26	1.61
Jan 26	1.54
Jan 26	1.62
Dec 25	1.61
Dec 25	1.75
Dec 25	1.73
Dec 25	1.87
Nov 25	1.88
Nov 25	1.53
Nov 25	1.69
Nov 25	0.88
Oct 25	1.25
Oct 25	0.86
Oct 25	0.99
Oct 25	0.8
Oct 25	0.85
Sep 25	0.82
Sep 25	0.76
Sep 25	0.64
Sep 25	0.59
Aug 25	0.5
Aug 25	0.56
Aug 25	0.59
Aug 25	0.47
Aug 25	0.59
Jul 25	0.68
Jul 25	0.68
Jul 25	0.71
Jul 25	0.66
Jun 25	0.64
Jun 25	0.73
Jun 25	0.81
Jun 25	1.01
May 25	0.76
May 25	0.71
May 25	0.83
May 25	0.39
May 25	0.44
Apr 25	0.42
Apr 25	0.36
Apr 25	0.4
Apr 25	0.37
Mar 25	0.44
Mar 25	0.49
Mar 25	0.51
Mar 25	0.52
Feb 25	0.51
Feb 25	0.58
Feb 25	0.76
Feb 25	0.74
Jan 25	0.67
Jan 25	0.7
Jan 25	0.77
Jan 25	0.58
Jan 25	0.67
Dec 24	0.64
Dec 24	0.67
Dec 24	0.79
Dec 24	0.93
Nov 24	1.07
Nov 24	0.53
Nov 24	0.85
Nov 24	1.1
Nov 24	0.91
Oct 24	0.96

No video analysis for this stock yet. Request one from our team.

News: CABA

seekingalpha.com · 14 Sep 2026

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

globenewswire.com · 1 Sep 2026

Cabaletta Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.

globenewswire.com · 13 Aug 2026

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

seekingalpha.com · 26 Jun 2026

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying

Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.